Domov › Rakovina vaječníkov › Colorado › Denver
Klinické štúdie Rakovina vaječníkov v meste Denver, CO
16 štúdií pre Rakovina vaječníkov hľadá účastníkov v zariadeniach v meste Denver a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
The Vanguard Study: Testing a New Way to Screen for Cancer
Prebieha náborVítaní zdravých dobrovoľníkov
- Kaiser Permanente-Franklin, Denver
A Study of PHST001 in Advanced Solid Tumors
Prebieha náborFáza 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One, Denver
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Prebieha náborFáza 1
- Sarah Cannon Research Institute at HealthOne, Denver
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Prebieha náborFáza 1/2
- Rocky Mountain Cancer Center, Denver
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Prebieha náborFáza 1
- SCRI at HealthOne, Denver
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
Prebieha náborFáza 1
- Sarah Cannon Research Institute at HealthONE /ID# 278785, Denver
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Prebieha náborFáza 3
- AdventHealth Medical Group - Porter, Denver
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Prebieha náborFáza 1/2
- SCRI at HCA Health One, Denver
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Prebieha náborFáza 1
- Sarah Cannon Research Institute - Denver DDU, Denver
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Prebieha náborFáza 1
- Normunity Investigational Site, Denver
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Prebieha náborFáza 3
- Cancer Center of Colorado at Sloan's Lake, Denver
- UCHealth - Cherry Creek, Denver
- Saint Joseph Hospital - Cancer Centers of Colorado, Denver
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Prebieha náborFáza 1/2
- Rocky Mountain Cancer Center, Denver
- Sarah Cannon Research Institute at HealthONE, Denver
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Prebieha náborFáza 1/2
- Research Site, Denver
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Prebieha náborFáza 1
- Sarah Cannon Research Institute at HealthONE, Denver
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Prebieha náborFáza 1
- Dren Investigational Site, Denver
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Prebieha náborObservačná štúdia
- Massive Bio SYNERGY-AI site, Denver
Štúdie Rakovina vaječníkov v iných mestách
- Houston, TX89 štúdií
- New York City, NY69 štúdií
- Boston, MA61 štúdií
- Los Angeles, CA50 štúdií
- Nashville, TN49 štúdií
- Arlington, VA46 štúdií
- Philadelphia, PA44 štúdií
- Columbus, OH39 štúdií
- St. Louis, MO38 štúdií
- Chicago, IL36 štúdií
- San Antonio, TX31 štúdií
- Cleveland, OH30 štúdií
Iné štúdie v Denver
- Metastatická rakovina29 štúdií
- Rakovina prsníka29 štúdií
- Nemalobunkový karcinóm pľúc27 štúdií
- Mnohonásobný myelóm27 štúdií
- Kolorektálny karcinóm23 štúdií
- Melanóm19 štúdií
- Rakovina prostaty19 štúdií
- Rakovina (všetky typy)18 štúdií
- Rakovina pľúc16 štúdií
- Rakovina endometria15 štúdií
- Non-Hodgkinov lymfóm14 štúdií
- Rakovina pankreasu13 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.